Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Active Biotech Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.	Sweden	ACTI
ACTUATE THERAPEUTICS, INC. Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.	United States of America	ACTU
AcuCort AB Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.	Sweden	ACUC
Acurx Pharmaceuticals, Inc. Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.	United States of America	ACXP
Adagene Inc. Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.	United States of America	ADAG
Adaptimmune Therapeutics PLC Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.	United States of America	ADAP
ADBIOTECH Co.,Ltd. Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.	South Korea	179530
ADC Therapeutics SA Develops targeted antibody-drug conjugates for hematological and solid tumors.	United States of America	ADCT
Addex Therapeutics Ltd. Developing novel oral allosteric modulators to treat neurological disorders.	United States of America	ADXN
ADIAL PHARMACEUTICALS, INC. Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.	United States of America	ADIL